Dec 20 (Reuters) - Bausch Health Companies Inc BHC.TO :
* BAUSCH HEALTH LICENSES NOVALIQ'S NOV03 INVESTIGATIONAL TREATMENT FOR DRY EYE DISEASE ASSOCIATED WITH MEIBOMIAN GLAND DYSFUNCTION
* BAUSCH HEALTH COMPANIES INC - NOVALIQ IS ELIGIBLE TO RECEIVE UPFRONT AND MILESTONE PAYMENTS
* BAUSCH HEALTH COMPANIES INC - A PHASE 3 STUDY IS UNDERWAY FOR NOV03, AND CO ANTICIPATES STARTING AN ADDITIONAL PHASE 3 STUDY IN 2020
* BAUSCH HEALTH COMPANIES INC - ACQUIRED EXCLUSIVE LICENSE FOR COMMERCIALIZATION AND DEVELOPMENT IN U.S. & CANADA OF INVESTIGATIONAL TREATMENT NOV03
* BAUSCH HEALTH COMPANIES INC - NOVALIQ IS ALSO ELIGIBLE TO RECEIVE SALES ROYALTIES
* BAUSCH HEALTH - HAS RIGHT TO PURSUE DEVELOPMENT & COMMERCIALIZATION OF NOV03 FOR DED AND COMBINATION PRODUCTS IN U.S. & CANADA
* BAUSCH HEALTH - NOVALIQ WILL BE ELIGIBLE TO RECEIVE ADDITIONAL UNDISCLOSED MILESTONE PAYMENTS PLUS ROYALTIES FOR ANY RESULTING COMBINATION PRODUCTS